HCQ has demonstrated in-vitro activity against SARS-CoV-2 and shown to be clinically beneficial in several small single-centre studies with significant limitations.
The post Health ministry recommends tocilizumab, HCQ, plasma therapy for patients in the moderate stage of COVID-19 appeared first on Firstpost.